Oragenics Receives NYSE American Deficiency Letter Regarding Continued Listing Standards

Oragenics, Inc. (NYSE American: OGEN) announced it received a deficiency letter from NYSE American LLC on August 26, 2026, indicating non-compliance with continued listing standards. Specifically, the company's stockholders' equity is below the $4 million threshold required for companies reporting losses in three of their four most recent fiscal years. The company also provided updates on its Phase IIa clinical trial and U.S. regulatory pathway.